Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study

Table 2 Evaluation of the laboratory parameters in the patients who received ferric carboxymaltose

Variables	Pre-therapy	Post-therapy	P value
Hemoglobin (mg/dL)	8.5 (5.8-10)	10.1 (7.8-13.7)	< 0.0001
Haematocrit (%)	27.8 (19.7-32.29)	33 (25.9-42.8)	< 0.0001
Ferritin (ng/dL)	23.79 (0.5-475.4)	100.38 (4.26-826.1)	0.0008
Iron (mcg/dL)	15 (4-43)	26 (10-64.52)	< 0.0001
STAT (mcg/dL)	3.5 (1-21)	9 (2-26.3)	0.01
MCV (fL)	74.6 (57.8-92.9)	80.8 (64.4-97.8)	0.05
HCM (pg)	22.3 (14.4-37.2)	23.6 (18.5-30.7)	0.15
MCHC (g/dL)	30.1 (24.9-38.8)	30.65 (26.4-33.9)	0.48
Platelets (× 10³/µL)	410 (200-888)	321 (201-708)	0.19

Numerical variables are described in the median (minimum and maximum). n = 25. Unpaired t-test (Mann Whitney) with P < 0.05. MCV: Mean Corpuscular Volume; HCM: Mean Corpuscular Hemoglobin; MCHC: Mean Corpuscular Hemoglobin Concentration; STAT: Transferrin saturation.